Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases.

Abstract

BACKGROUND:

The role of adjuvant chemotherapy for stage IV colorectal cancer has so far been under-investigated. The aim of this study was to assess the feasibility and short-term outcome of adjuvant chemotherapy with the FOLFOX regimen following liver resection for patients with colorectal liver metastasis (CRLM).

METHODS:

From May 2005 to September 2010, 86 patients with CRLM underwent hepatic resection in the Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University. Of these patients, 24 received FOLFOX4 or modified FOLFOX6 as postoperative adjuvant chemotherapy.

RESULTS:

Nineteen male and 5 female patients received adjuvant chemotherapy following liver resection. Twenty-one (87.5 %) of these patients completed 6 cycles of adjuvant chemotherapy. Five patients required a dose reduction due to neutropenia, and the dose intensities of oxaliplatin and 5-FU were 93.6 and 94.1 %, respectively. There were no severe adverse events from the treatments. The median follow-up period was 48.4 months. Recurrences developed in 12 patients, and 3 patients died during the follow-up period. The 3- and 5-year disease-free survival and overall survival were 51.6 and 45.1 % and 95.5 and 76.0 %, respectively.

CONCLUSIONS:

Adjuvant FOLFOX is feasible and might provide a good prognosis for CRLM patients who undergo liver resection.

• Authors: Yasuo Sakamoto, Toru Beppu, Yuji Miyamoto, Hirohisa Okabe, Satoshi Ida, Katsunori Imai, Akira Chikamoto, Masayuki Watanabe, Hiroshi Takamori, Hideo Baba
• Journal: Journal of hepato-biliary-pancreatic sciences (J Hepatobiliary Pancreat Sci) Vol. 20 Issue 3 Pg. 307-12 (Mar 2013) ISSN: 1868-6982 [Electronic] Japan
• PMID: 22610308 (Publication Type: Journal Article)

Chemical References

• Organoplatinum Compounds
• Leucovorin
• Fluorouracil

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Chemotherapy, Adjuvant
• Colorectal Neoplasms (pathology)
• Feasibility Studies
• Female
• Fluorouracil (adverse effects, therapeutic use)
• Hepatectomy
• Humans
• Leucovorin (adverse effects, therapeutic use)
• Liver Neoplasms (drug therapy, secondary, surgery)
• Male
• Middle Aged
• Neoplasm Staging
• Organoplatinum Compounds (adverse effects, therapeutic use)
• Prospective Studies
• Survival Rate
• Treatment Outcome